Zoetis Inc. $ZTS Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 10.8% in the 2nd quarter, Holdings Channel reports. The fund owned 1,839,811 shares of the company’s stock after selling 223,359 shares during the period. Hsbc Holdings PLC’s holdings in Zoetis were worth $132,132,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of ZTS. Prosperity Bancshares Inc purchased a new position in Zoetis in the 4th quarter worth about $25,000. Cassaday & Co Wealth Management LLC purchased a new stake in Zoetis during the first quarter valued at about $28,000. Elyxium Wealth LLC purchased a new stake in Zoetis during the fourth quarter valued at about $32,000. Root Financial Partners LLC boosted its holdings in shares of Zoetis by 66.5% in the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after buying an additional 103 shares during the period. Finally, Wellington Grp LLC increased its position in shares of Zoetis by 6,675.0% in the first quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after acquiring an additional 267 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Up 0.2%

Zoetis stock opened at $77.29 on Wednesday. Zoetis Inc. has a twelve month low of $71.00 and a twelve month high of $156.49. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The firm has a market cap of $31.94 billion, a PE ratio of 12.73, a P/E/G ratio of 1.80 and a beta of 0.74. The firm’s 50 day moving average price is $75.66 and its two-hundred day moving average price is $96.47.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. During the same quarter last year, the business posted $1.76 EPS. The company’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, research analysts predict that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ZTS shares. HSBC cut their price target on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a report on Monday, July 6th. Cantor Fitzgerald set a $94.00 price objective on shares of Zoetis in a research report on Tuesday. JPMorgan Chase & Co. reduced their target price on Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, August 7th. Argus reiterated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Finally, Citigroup dropped their price target on Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $107.43.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.